Bivalent Respiratory Syncytial Virus prefusion F vaccine(Pfizer)

Moderna's mRESVIA vaccine received MHRA approval in February 2025 for adults aged 60 and older, joining GSK's Arexvy and Pfizer's Abrysvo in the expanding RSV vaccine market.

The FDA has approved Pfizer's Abrysvo vaccine for preventing lower respiratory tract disease caused by RSV in adults aged 60 and older, mirroring GSK's Arexvy approval.

The FDA has approved Abrysvo, Pfizer's RSV vaccine, for adults aged 18-59 at increased risk of RSV-associated lower respiratory tract disease.

The FDA has approved Moderna's mResvia (mRNA-1345), an mRNA vaccine, for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and over.

A recent study reveals that older, immunocompromised adults exhibit a weaker antibody response to RSV vaccines compared to healthy individuals.